TY  - INPR
TI  - A global research priority agenda to advance public health responses to fatty liver disease
N1  - © 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver under a Creative Commons license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ID  - discovery10173222
Y1  - 2023/06/20/
UR  - https://doi.org/10.1016/j.jhep.2023.04.035
PB  - Elsevier BV
JF  - Journal of Hepatology
A1  - Lazarus, Jeffrey V
A1  - Mark, Henry E
A1  - Allen, Alina M
A1  - Arab, Juan Pablo
A1  - Carrieri, Patrizia
A1  - Noureddin, Mazen
A1  - Alazawi, William
A1  - Alkhouri, Naim
A1  - Alqahtani, Saleh A
A1  - Arrese, Marco
A1  - Bataller, Ramon
A1  - Berg, Thomas
A1  - Brennan, Paul N
A1  - Burra, Patrizia
A1  - Castro-Narro, Graciela E
A1  - Cortez-Pinto, Helena
A1  - Cusi, Kenneth
A1  - Dedes, Nikos
A1  - Duseja, Ajay
A1  - Francque, Sven M
A1  - Hagström, Hannes
A1  - Huang, Terry T-K
A1  - Wajcman, Dana Ivancovsky
A1  - Kautz, Achim
A1  - Kopka, Christopher J
A1  - Krag, Aleksander
A1  - Miller, Veronica
A1  - Newsome, Philip N
A1  - Rinella, Mary E
A1  - Romero, Diana
A1  - Sarin, Shiv Kumar
A1  - Silva, Marcelo
A1  - Spearman, C Wendy
A1  - Tsochatzis, Emmanuel A
A1  - Valenti, Luca
A1  - Villota-Rivas, Marcela
A1  - Zelber-Sagi, Shira
A1  - Schattenberg, Jörn M
A1  - Wong, Vincent Wai-Sun
A1  - Younossi, Zobair M
A1  - Healthy Livers, Healthy Lives, Collaborators
KW  - Delphi method
KW  -  Global health
KW  -  NAFLD/NASH
KW  -  Non-communicable disease (NCD)
KW  -  Steatotic liver disease
N2  - BACKGROUND & AIMS: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. METHODS: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. RESULTS: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of 'agree' responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement ('agree' + 'somewhat agree'); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% 'agree'), 13 priorities had <80% 'agree', with greater reliance on 'somewhat agree' to achieve >90% combined agreement. CONCLUSIONS: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. IMPACT AND IMPLICATIONS: An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat.
AV  - public
ER  -